Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754657 | 0.84 | SMN1; SMN2 (0.40) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL2649515 | 0.84 | MAPT (0.40) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL2650690 | 0.84 | SMN1; SMN2 (0.40) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL192118 | 0.84 | MAPT (0.40) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL28041813 | 0.83 | KDM4E (0.41) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL3560430 | 0.83 | KDM4E (0.46) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL1341382 | 0.80 | SMN1; SMN2 (0.39) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL25784214 | 0.77 | TSHR (0.44) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL23146727 | 0.77 | NPC1 (0.53) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL21746957 | 0.76 | NFKB1 (0.55) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402349-B1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-20140371249-A1 | CRYSTAL OF A FREE TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371249-A1 | CRYSTAL OF A FREE TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371249-A1 | CRYSTAL OF A FREE TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-2810945-A1 | Dihydrochloride salt of a tricyclic pyrazolopyrimidine derivative | Daiichi Sankyo Company, Limited (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-8846703-B2 | Crystal of a free tricyclic pyrazolopyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8846703-B2 | Crystal of a free tricyclic pyrazolopyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8846703-B2 | Crystal of a free tricyclic pyrazolopyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8815880-B2 | Crystal of tricyclic pyrazolopyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8815880-B2 | Crystal of tricyclic pyrazolopyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8236813-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8236813-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| WO-2012026433-A1 | FREE CRYSTAL OF TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | 第一三共株式会社 (JP) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012026434-A1 | CRYSTAL OF TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | 第一三共株式会社 (JP) | 2012-03-01 | — | — | WO | disclosed |
| EP-2402349-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402349-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-24 | — | — | US | disclosed |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-24 | — | — | US | disclosed |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-24 | — | — | US | disclosed |
| WO-2010098344-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | 第一三共株式会社 (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371249-A1 | CRYSTAL OF A FREE TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | HSP90AB2P, HSP90B1, HSP90AA1 | MAPT 2315/4885SMN1; SMN2 4526/4885NPC1 2078/4885 |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | HSP90AB1, HSP90B1, HSP90AA1 | MAPT 1643/4885SMN1; SMN2 4213/4885NPC1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.